Aims : To determine incidence and five years survival rate of renal parenchyma tumours by TNM stage using cases recorded in seven French departments cancer registries. To estimate overall and with metastasis cancer prevalence, at the end of 2004, when diagnosed over the period 2000-2004. Method : Identification of patients using the databases of seven cancer registries. Data collected trough medical records and administrative data (vital states). Assessment of raw global survival rate using Kaplan Meier curves. Determination of global prevalence by summing 2000-2004 annual incident cases for which corresponding global survival data have been applied. Same method for the estimation of prevalence without metastases. Prevalence with metastases is global prevalence minus prevalence without metastases. Results :597 cases were identified and analized. 84% of cases consisted of clear cell adenocarcinoma. Thus, the standardised levels of incidence (worldwide reference population) are estimated to be 9.91 per 100 000 men and 3.75 per 100 000 women. Stages I, II, III and IV had specific incidences respectively of 4.7, 1.1, 1.9 and 2.7 per 100 000 subjects. The 5 years survival rate in men and women was respectively 55% (CI95 : 50-60) and 65% (CI95 : 58-71). Survival decreased with age and with stage extension. The national number of cases is estimated to be 6 482 cases. Accordingly, the estimated partial global prevalence is 29 300 cases , including 4 860 with metastasis (16,6%) , this rate increases with age : from 11% for patients aged less than 60 years to 29% for patients aged 80 years and over. Conclusion : This study is the first one to give an estimation of specific parenchyma cancer by stage incidence, on a population base. On this base, this study also provides prevalence estimations for evolutive cancers.